Demo Sign up Log In

Esperion Therapeutics Inc (ESPR)

R&D to Revenue

11.87%

Fiscal year · Period ending: Dec 31, 2025

ESPR R&D to Revenue

Latest reported11.87%period endingDec 31, 2025

Latest reported11.87%period endingDec 31, 2025

ESPR FY R&D/Revenue (0.00% → 11.87%)

Latest values, visible window

High-resolution chart · PNG

ESPR r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Esperion Therapeutics Inc R&D to Revenue — Annual fiscal periods
Period ending	R&D to Revenue
Dec 31, 2025	11.87%
Dec 31, 2024	13.9139%
Dec 31, 2023	74.0171%
Dec 31, 2022	157.5714%
Dec 31, 2021	135.0912%
Dec 31, 2020	64.5739%
Dec 31, 2019	118.365%
Dec 31, 2018	92.9605%
Dec 31, 2017	0%
Dec 31, 2016	0%
Dec 31, 2015	0%
Dec 31, 2014	0%
Dec 31, 2013	0.3218%
Dec 31, 2012	0%
Dec 31, 2011	0%
Dec 31, 2002	0%
Dec 31, 2001	0%
Dec 31, 2000	1,089,450%
Dec 31, 1999	0%

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.